About this trial
Cervical cancer is the leading cause of cancer death among women in sub-Saharan Africa, despite the existence of effective prevention and screening methods. Because vaccination rates against human papillomavirus (causing nearly all cervical cancers) are still insufficient in some low-resource countries, early detection and treatment of cervical lesions at risk of progressing to cancer are crucial components of cervical cancer control. Therefore, it is essential to find the most reliable and appropriate screening strategy in the context of low-resource countries in order to identify women in need of treatment and thus prevent the development of cervical cancer. The objective of our study is to compare two different methods of cervical cancer screening adapted to low-resource settings, in two study centers in Cameroon.
Eligibility criteria
Qualifiers
HIV-negative women aged 30-49 and HIV-positive women aged 25-49 years old
Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF).
Disqualifiers
Pregnancy at the time of screening
Previous hysterectomy
Known cervical cancer
Symptoms of cervical cancer (e.g. metrorrhagia, known pelvic mass)
Trial design
Treatments tested in this trial
- HPV genotyping
- Visual inspection after application of acetic acid
Treatment groups
Sponsors and collaborators
Prof. Patrick Petignat
Lead sponsor
University Hospital, Geneva
Sponsor institution
University Hospital, Geneva
Collaborator
Bafoussam Regional Hospital, Cameroon
Collaborator
Dschang District Hospital, Cameroon
Collaborator
University of Dschang
Collaborator